PerAF APAC: Persistent Atrial Fibrillation (AF) (Asia Pacific) Observational Study
Study Details
Study Description
Brief Summary
The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug refractory, symptomatic persistent atrial fibrillation when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The PerAF APAC trial is a prospective, single arm, non-randomized, observational, post-market clinical investigation. Approximately 100 subjects will be enrolled at up to 15 sites in South Korea, Singapore, Hong Kong, Taiwan, and India. Centers in other countries within APAC may be approached for participation in the clinical investigation as needed. Subjects will be followed for 15-months after their initial ablation procedure. The primary effectiveness and safety endpoints will be evaluated through 15-months. A core lab will independently assess AF/AFL/AT recurrence via Holter monitoring at the 6-month and 15-month follow-up visits. All serious adverse events (SAEs) will be independently adjudicated by qualified physicians not participating in the trial
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Drug refractory, symptomatic persistent atrial fibrillation Asian population |
Device: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)
TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
|
Outcome Measures
Primary Outcome Measures
- Rate of device and/or procedure-related serious adverse events [7-days]
device and/or procedure-related serious adverse events are pre-defined as below with onset within 7-days of any ablation procedure that uses the TactiCath SE catheter (initial or repeat procedure performed ≤180 days of initial procedure) Atrioesophageal fistula - assessed through 15 months Cardiac tamponade/perforation - assessed through 15 months Death Heart block Myocardial infarction (MI) Pericarditis - pleuritic symptoms >7 days and/or requires hospitalization >24 hrs for reasons other than observational purposes only Phrenic nerve injury resulting in diaphragmatic paralysis Pneumothorax Pulmonary edema (respiratory insufficiency) Pulmonary vein stenosis - assessed through 15 months Stroke/cerebrovascular accident Thromboembolism Transient ischemic attack Vascular access complications (including major bleeding events)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent
-
Documented symptomatic persistent AF, defined as continuous AF sustained >7-days but <1 year documented by:
-
Physician's note AND one of the following:
-
24-hr Holter showing continuous AF within 90-days of the procedure OR
-
2 ECGs (from any form of rhythm monitoring) showing continuous AF, taken at least 7-days apart
-
Refractory or intolerant to at least one Class I or III antiarrhythmic drug (AAD) as evidenced by recurrent symptomatic AF NOTE: Intolerant = unable, unwilling, or refusal to take AADs
-
≥18 years of age
-
Able and willing to complete all pre-, post-, and follow-up testing and requirements
Exclusion Criteria:
-
Continuous AF >12 months (longstanding persistent AF)
-
Previous left atrial (LA) surgical or catheter ablation for AF
-
Any cardiac procedure within 90-days prior to initial procedure (Diagnostic procedures with no intervention are not considered a surgical or percutaneous surgical procedure)
-
Coronary artery bypass graft (CABG) surgery within 6-months (180-days) prior to initial procedure
-
Valvular cardiac surgical/percutaneous procedure (i.e. ventriculotomy, valve repair or replacement and/or presence of a prosthetic or mechanical valve)
-
Any carotid stenting or endarterectomy
-
Documented or known left atrial thrombus on imaging
-
Left atrial (LA) diameter >50 mm (parasternal long axis view or by CT)
-
Left Ventricular Ejection Fraction (LVEF) <40%
-
Unable to take anticoagulation medication due to contraindication or intolerance
-
History of blood clotting or bleeding abnormalities
-
Myocardial Infarction (MI), acute coronary syndrome, Percutaneous coronary intervention (PCI) within the 3-months (90-days) prior to the initial procedure
-
Documented thromboembolic event (including TIA) within 12-months (365 days) prior to the initial procedure
-
Rheumatic heart disease
-
Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
-
Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2)
-
Awaiting cardiac transplantation or other cardiac surgery within 12-months (365 days) following the initial ablation procedure
-
Unstable angina at the time of the initial procedure
-
Acute illness or active systemic infection or sepsis
-
AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, major surgical procedure in the preceding 3-months, or other reversible or non-cardiac cause
-
Diagnosed atrial myxoma
-
Presence of implanted implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)
-
Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
-
Significant congenital anomaly or other anatomic or comorbid medical problem that in the opinion of the investigator would preclude enrollment in this study or compliance with the follow-up requirements or impact the scientific soundness of the clinical trial results
-
Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
-
Enrollment in an investigational study evaluating another device, biologic, or drug that may interfere with this clinical investigation at the time of the initial procedure or within 30 days prior to the initial procedure
-
Presence of any condition that precludes appropriate vascular access or manipulation of catheter
-
Life expectancy less than 12-months
-
Body mass index >40 kg/m2
-
Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
-
Renal failure requiring dialysis
-
Presence of other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
-
History of atriotomy or ventriotomy
-
Implanted left atrial appendage occlusion device
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Prince of Wales Hospital | Hong Kong | Hong Kong | ||
| 2 | Sejong Hospital | Bucheon | Korea, Republic of | ||
| 3 | Severance Hospital, Yonsei University Health System | Seoul | Korea, Republic of | ||
| 4 | Asan Medical Centre | Soeul | Korea, Republic of | ||
| 5 | National Heart Centre Singapore | Singapore | Singapore | ||
| 6 | National University Hospital | Singapore | Singapore | ||
| 7 | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | Taiwan | ||
| 8 | Taipei Veterans General Hospital | Taipei | Taiwan | ||
| 9 | Phramongkutklao Hospital | Bangkok | Thailand |
Sponsors and Collaborators
- Abbott Medical Devices
Investigators
- Study Director: Kristin Ruffner, Abbott
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ABT-CIP-10295